Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02791191) enrolled 316 people with mild Alzheimer's disease across three groups: 55 received a 3 mg dose of a study drug called LY3202626, 128 received a 12 mg dose, and 133 received a placebo (a dummy treatment with no active ingredient). The trial ran for 52 weeks and was primarily measuring changes in brain scans using a special imaging technique called a PET scan, which was looking at a protein called tau — a substance that builds up in the brains of people with Alzheimer's disease. It is worth noting that relatively few participants completed the full study: 17 in the 3 mg group, 17 in the 12 mg group, and 13 in the placebo group. The reported data shows that on the primary measure — the change in tau PET scan readings after 52 weeks — all three groups showed a very small increase from their starting point. The 3 mg group had a reported change of +0.02 units, the 12 mg group +0.03 units, and the placebo group +0.01 units, all on a standardised imaging scale. For secondary measures, the reported data shows changes in a blood-based marker related to amyloid (another protein linked to Alzheimer's disease): the 3 mg group had a change of approximately −258.7 ng/L, the 12 mg group −286.1 ng/L, and the placebo group −12.0 ng/L for one form of amyloid measured (Aβ1-40), with similar patterns seen for other amyloid forms measured. Regarding brain scan abnormalities (ARIA), small percentages of participants across all groups had these findings recorded, ranging from 0% to around 7.5% depending on the type and group. Suicidal thoughts (as measured by a standard questionnaire) were reported as treatment-emergent in approximately 7.3% of the 3 mg group, 7.1% of the 12 mg group, and 3.8% of the placebo group, though the data does not allow any conclusions about cause. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Alzheimer's Disease Trial, Terminated
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- A qualified doctor has diagnosed you with mild Alzheimer's disease dementia based on recognised medical guidelines.
- You scored between 20 and 26 (inclusive) on a standard memory and thinking test called the Mini-Mental State Examination at your screening appointment.
- A special brain scan (called a florbetapir PET scan) showed signs of a protein buildup in the brain linked to Alzheimer's disease.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have a significant brain or nervous system condition other than Alzheimer's, such as another type of dementia, a serious brain infection, Parkinson's disease, multiple concussions, or epilepsy or repeated seizures (childhood febrile seizures may be an exception — confirm with trial site).
- You have an eye condition that would make it difficult to reliably test your vision or examine the back of your eye.
- You are currently taking certain strong medications that affect how the body breaks down drugs through a liver enzyme called CYP3A (confirm with trial site which medications apply).
- You have a known sensitivity or allergic reaction to florbetapir or a related substance called ¹⁸F-AV-1451, which are used in the brain scans.
- You are unable to have an MRI or PET scan, or you have very difficult-to-access veins for blood tests.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
If you need support right now
This page includes language about suicide and self-harm, because that is how the trial's eligibility criteria are written. If reading it has been hard, you do not have to keep going. The services below are free, confidential, and answered by people trained for exactly this.
If you or someone else is in immediate danger, call 000.
- Lifeline — 24/7 crisis support: 13 11 14
- Suicide Call Back Service — 24/7 counselling: 1300 659 467
- 13YARN — 24/7, for Aboriginal and Torres Strait Islander people: 13 92 76
- Beyond Blue — 24/7 mental health support: 1300 22 4636
- Kids Helpline — 24/7, free and private for anyone aged 5 to 25: 1800 55 1800
- headspace — mental health support for 12 to 25 year olds: headspace.org.au
- Emergency: 000
Outside Australia? The numbers above are Australian and will not work from overseas. Find a Helpline is a free directory of crisis lines in over 130 countries, run by ThroughLine with the International Association for Suicide Prevention. If you are in immediate danger, call your local emergency number.
Voxsanity is not a crisis service, and nothing on this page is medical advice. More Australian services are listed on our support lines page.
Trial contact details on record
Principal Investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Australian sites
This trial is not accepting new participants. These are the contact details ClinicalTrials.gov holds for it, kept here for reference. They are not an invitation to enrol, and the sites listed may no longer be running this trial.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 10 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Change From Baseline in ¹⁸F-AV-1451 Positron Emission Tomography (PET) Standard Uptake Value Ratio (SUVr) at 52 Weeks
Other options
Data last synced from ClinicalTrials.gov: 7 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.